FRONT PAGE AMPYRA AUBAGIO AVONEX BETASERON COPAXONE EXTAVIA
Stan's Angels MS News Channel on YouTube GILENYA NOVANTRONE REBIF RITUXAN TECFIDERA TYSABRI
 Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
CLICK ON THE RED BUTTON BELOW
You'll get FREE Breaking News Alerts on new MS treatments as they are approved
MS NEWS ARCHIVES: by week

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
and
Medical Director-Rocky Mountain MS Center


Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an M.D....my Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore


This page is powered by Blogger. Isn't yours?

Sunday

 

Multiple sclerosis: Scientists ID cause of movement, balance problems





























Image source: SNOWBRAINS


New research into the causes of the excessive inflammation that drives multiple sclerosis has identified a faulty "brake" within immune cells, a brake that should be controlling the inflammation. This points to a potential target for developing new therapies to treat multiple sclerosis and could have important implications for other autoimmune diseases, such as the colon disease colitis and the chronic skin condition atopic dermatitis.
Read more »

Labels:


 

Five Women in the MS Community Help Me Feel #strongerthanMS: Who Helps You?




















Did you ever hear the question, “If you could have anyone sit at your table, alive or dead, who would you choose?” When asked this question I’d usually answer with a variation of people like Eleanor Roosevelt, Cary Grant, Joan of Arc, Abraham Lincoln, Golda Meir, Mother Teresa, Albert Einstein and Frank Sinatra.
Read more »

Labels:


 

Multiple sclerosis patients, doctors assess costs vs. benefits of experimental treatment























Trina Cooper

How far would you go for a possible cure to an incurable disease? How much money would you spend? How great a risk could you accept?
Read more »

 

Just Get Over It: The Fallacy of Closure

















Just get over it. It’s in the past, forget about it.

These are shaming, dismissive words, as advocate/songwriter Michael Skinner so eloquently points out and explores in his support work. We’ve all heard some version of this about a tragedy, a drama, an injustice. Like a scolding older sibling, we’ve even taken ourselves aside and told our infantile alter-egos to buck up. It’s a pop psychology anthem for how to cope with the ever-accumulating baggage we all collect if we live long enough.
Read more »

 

Cognitive rehabilitation in multiple sclerosis: a randomized controlled trial: STUDY
































Image source: PRWEB


Read more »

Labels: ,


Saturday

 

5 Pieces of Advice for the Newly Diagnosed















I’m a few years into the MS game now, and I often find myself exchanging e-mails with people who have just been diagnosed. I never hesitate to extend a helping hand and a few words of advice, especially since I was on the receiving end not too long ago. I’ll never forget the people (some of whom were complete strangers) who were kind enough to talk to me, and help me through that initial period after diagnosis. My hope is that I can pay it forward as much as possible.
Read more »

Labels:


 

Health Beat: Massage for MS: VIDEO






















Shavonne Thurman was in her 20s when numbness in her abdomen and double vision sent her to the doctor. She was diagnosed with multiple sclerosis, which has slowly progressed.
Read more »

Labels:


 

Singer Releases Song About MS Recovery After Receiving Stem Cell Therapy





















Kristen King


Singer Kristen King began to experience fatigue, muscle weakness and later paralysis in some parts of the body in 2013, and it came as a shock when she was diagnosed with multiple sclerosis (MS). After struggling to deal with the unfortunate news and her new reality, the singer has now launched a new song entitled “Impervious” about her battle with the disease, which led her to undergo a stem cell treatment.
Read more »

Labels:


 

Yoga for Multiple Sclerosis Patients

























There are 400,000 cases of Multiple Sclerosis in the U.S. but a doctor and a yoga instructor in Great Falls are trying to help those with the disease in an alternative way a special yoga class for those suffering from M.S.
Read more »

 

Longitudinal assessment of immuno-metabolic parameters in multiple sclerosis patients during treatment with Copaxone (glatiramer acetate)































Image source: MYELITETMOI
Read more »

Labels: ,


Friday

 

Hawaii committee passes medical marijuana dispensries bill






















Teri Heede, 60, talks about a bill to set up medical marijuana dispensaries on Monday, May 4, 2015 in Honolulu. Medical marijuana was legalized in Hawaii nearly 15 years ago, but patients like Heede, who has multiple sclerosis, have been left to grow the drug on their own or buy it on the black market. (AP Photo/Cathy Bussewitz)
Story Source: The above story is based on materials provided by WASHINGTONTIMES
Note: Materials may be edited for content and length
Click here to see more

Labels:


 

Two existing drugs may potentially become new drug target for multiple sclerosis































Image Source: UCDENVER

Two drugs already on the market -- an antifungal and a steroid -- may potentially take on new roles as treatments for multiple sclerosis. According to a study published in Nature today, researchers discovered that these drugs may activate stem cells in the brain to stimulate myelin producing cells and repair white matter, which is damaged in multiple sclerosis. The study was partially funded by the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health.
Read more »

Labels:


 

Multiple Sclerosis, Crohn’s Drug Used in HIV Targeted Therapy





























Multiple sclerosis (MS) and Crohn’s disease drug Tysabri (Biogen Idec Inc.) can be used to fight against human immunodeficiency virus (HIV), according to research published in PLOS Pathogens.
Read more »

 

Your Healthy Family: Living with MS: VIDEO


Rob Harasimowicz

News 5 sat down with a local man living with Multiple Sclerosis who's now an ambassador for the MS society.
Read more »

Labels:


 

Patients characteristics influencing the longitudinal utilization of steroids in multiple sclerosis – an observational study: STUDY

Thursday

 

Is This Biogen's Next Billion-Dollar Blockbuster?
















Biogen (NASDAQ: BIIB) recently announced that its next-generation multiple sclerosis drug Zinbryta has been submitted for FDA approval. The submission clears the way for an FDA decision early next year, and potentially sets the stage for Biogen to strengthen its dominance as a leader in multiple sclerosis treatment.
Read more »

 

Medicinova completes enrollment for phase 2b study of experimental progressive MS treatment.



MediciNova, Inc., a publicly-traded biopharmaceutical company developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical needs, recently announced that the National Institute of Neurological Disorders and Stroke (NINDS) notified the company of full enrollment of their ongoing clinical study evaluating ibudilast (MN-166) for the treatment of progressive multiple sclerosis. The trial randomization is aimed to be completed in about 4 to 6 weeks.
Read more »

 

New MS drug shows promise for those with aggressive disease

Barb Baird of Bridgeville sits with an IV in her arm for her 4th of 5 treatments of Lemtrada, a new drug used for patients with multiple sclerosis at Allegheny General Hospital on the North Side.

Diagnosed about 27 years ago with multiple sclerosis, Barb Baird said she has tried “every drug on the market” but still experiences periodic flare-ups that aggravate her dizziness and balance problems.
Read more »

Labels: , ,


 

Researchers Discover That “Complement,” an Array of Immune-System Proteins, May Be a Culprit in MS Memory Problems

Hippocampus MRI
Memory impairment and other cognitive changes are experienced by many people with MS, but the details of how this occurs are not clear. Now researchers supported in part by the National MS Society report evidence that a group of immune system proteins called “complement” may play a role in the loss of nerve connections (synapses) in the hippocampus, a part of the brain linked to memory. This study was published in Annals of Neurology by Drs. Iliana Michailidou, Valeria Ramaglia and colleagues in The Netherlands and Germany (Published online May 11, 2015).
Read more »

Labels: ,


 

Impaired sleep-associated modulation of post-exercise corticomotor depression in multiple sclerosis: STUDY

Wednesday

 

Bluffton family seeks help for son diagnosed with MS































A family known for their outreach in the Lowcountry is looking for the community’s support for their son who is battling multiple sclerosis at 38 years old.
Read more »

 

Wild G Harding expected to end career





















Minnesota Wild goalie Josh Harding (37) makes a save on Washington Capitals center Michael Latta in this Nov 7, 2013 game at Verizon Center. Geoff Burke-USA TODAY Sports
Read more »

 

Allô! Mon Coco stands up for the fight against Multiple Sclerosis with the #SPCOCOCHALLENGE to help raise awareness, raise funds and to promote The Walk of Hope



In Québec, the month of May is to raise awareness and promote the autoimmune disease that attacks the central nervous system known as Multiple Sclerosis (MS). The breakfast restaurant chain known as Allô! Mon Coco, takes MS to heart, due to the fact that Mr. Tom Bountis, CEO of the business, has a sister diagnosed with this tragic illness. Therefore, Allô! Mon Coco will be taking the opportunity to promote MS by launching a challenge to the public.
Read more »

 

Free Cooling Equipment for People with MS — Apply Now!

























Max Kool Vest from Polar

With springtime finally making an appearance in much of the US, summer will be upon us before you can count down from one thousand. With the summer season also comes high temperatures, humidity—capable of gluing clothing to skin as soon as you step out the front door—and MS symptoms that can knock you on your butt, literally and figuratively.
Read more »

 

No prognostic value of routine cerebrospinal fluid biomarkers in a population-based cohort of 407 multiple sclerosis patients:: STUDY

Tuesday

 

WII FIT VIABLE TREATMENT FOR BALANCE OF PEOPLE WITH MULTIPLE SCLEROSIS
































Exercise through gaming or 'exergaming' could be a viable alternative to help people with Multiple Sclerosis live happier and more active lives, researchers at Teesside University have found.
Read more »

Labels: ,


 

UNSUNG HEROES:Melissa DeStefano brought Special Olympics and support group to Pottsgrove High School
























Team members announced their arrival at the Special Olympics venue by carrying a handmade banner around the track. Melissa DeStefano is at far right. Photo by Merrill Weber

In 2007, life skills teacher extraordinaire, Melissa DeStefano, brought Special Olympics to Pottsgrove High School. Then in 2013, she co-founded Falcon Friends, a PGHS organization that pairs regular education students with those who have special needs. On May 18, Special Olympics will again take place at Souderton Area High School. She accomplished all this while battling Multiple Sclerosis. For all of these reasons, Melissa DeStefano is an unsung hero.
Read more »

 

Jeanius Cake Break raises £350 for Multiple Sclerosis

























TeamJeanius fundraising for MS

Always the first to get involved in charitable events, the team at Jeanius hosted theirfirst ever Cake Break in Aid of Multiple Sclerosis on Tuesday 12thMay, raising a fantastic total of £350 for the charity.
Read more »

 

Amarantus Reports Preliminary Data From Blood-based Version of MSPrecise(R) Diagnostic for Multiple Sclerosis

-MSPrecise blood diagnostic shows statistically significant sensitivity and specificity for classifying presentation of multiple sclerosis-
-Data supports further research into blood-based approach -
SAN FRANCISCO, May 11, 2015 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on developing therapeutic and diagnostic products for neurological disorders and orphan indications, announced that it has reported preliminary data from the blood-based version of its MSPrecise® diagnostic, the Company's proprietary multiple sclerosis (MS) diagnostic test.
MSPrecise, a next-generation DNA sequencing (NGS) assay, measures DNA mutations found in rearranged immunoglobulin genes in immune cells (B cells) to identify patients with relapsing-remitting multiple sclerosis (RRMS) at first clinical presentation.
Results from the most recent MSPrecise validation study using cerebrospinal fluid (CSF) samples for MS, reported in January 2015, demonstrated an 86% sensitivity and 71% specificity in correctly identifying early-stage RRMS in subjects being evaluated for a demyelinating disease undergoing the current diagnostic standard of care (clinical evaluation, magnetic resonance imaging and oligoclonal banding tests), as adjudicated by an expert panel of physicians. When combined with oligoclonal banding tests (OCB), sensitivity improved to 96% and specificity improved to 83%.
Today, Amarantus Diagnostics, a wholly-owned subsidiary of Amarantus BioScience Holdings, Inc., reported preliminary MSPrecise blood assay results from the same study (collected concurrently with CSF from the same patients). In the study, preliminary results indicate that the MSPrecise blood assay exhibited an 81% sensitivity and 89% specificity for identifying early-stage RRMS in subjects being evaluated for a demyelinating disease undergoing the current diagnostic standard of care. These results have not yet been combined with OCB and will require replication prior to moving into a CLIA validation study.
"These early findings are encouraging, and provide a pathway to further define and refine the MSPrecise blood assay," commented Colin Bier, Chief Development Officer of Amarantus Diagnostics. "Of particular importance, in this initial blood study, is the promising and positive analytical performance. There is such a high rate of misdiagnosis of MS, especially upon first clinical presentation of this chronic and extremely debilitating disease, that a blood test would be of great benefit to patients and physicians. We are preparing MSPrecise CSF for a CLIA-enabling validation study and, in parallel, will actively continue research and development of the MSPrecise blood assay."
"MSPrecise is potentially a groundbreaking advancement for the diagnosis of multiple sclerosis. Based on the CSF validation data, we anticipate moving into a CLIA validation that is currently in the planning stages," added Gerald E. Commissiong, President & CEO of Amarantus BioScience Holdings, Inc. "The MSPrecise CSF assay, along with our LymPro Test® blood diagnostic for Alzheimer's disease, are the two of key assets in our diagnostics division. Together, MSPrecise and LymPro will allow Amarantus Diagnostics to very rapidly achieve critical mass as one of the premier neurodiagnostic testing companies in the world."
LymPro is currently available as a diagnostic assay for Investigational Use Only (IUO) in pharmaceutical therapeutic clinical development programs. Amarantus plans to advance MSPrecise and LymPro into CLIA validation studies in parallel later this year to prepare for the launch of MSPrecise and LymPro under the CLIA designation for marketing to the broader medical community in the United States.
About MSPrecise®
MSPrecise® is a proprietary next-generation DNA sequencing (NGS) assay for the identification of patients with relapsing-remitting multiple sclerosis (RRMS) at first clinical presentation. MSPrecise utilizes next-generation sequencing to measure DNA mutations found in rearranged immunoglobulin genes in immune cells initially isolated from cerebrospinal fluid. MSPrecise would augment the current standard of care for the diagnosis of MS by providing a more accurate assessment of a patient's immune response to a challenge within the central nervous system. This novel method of measuring changes in adaptive human immunity may also be able to discern individuals whose disease is more progressive and requires more aggressive treatment.
About LymPro Test®
The Lymphocyte Proliferation Test (LymPro Test®) is a diagnostic blood test that determines the ability of peripheral blood lymphocytes to withstand an external mitogenic stimulation that induces them to enter the cell cycle. It is believed that certain diseases, most notably Alzheimer's disease, are the result of compromised cellular machinery that leads to aberrant cell cycle re-entry by neurons. LymPro is unique in the use of peripheral blood lymphocytes (PBLs) as a surrogate for neuronal cell function, suggesting a common immune-based relationship between PBLs and neurons in the brain.
About Amarantus BioScience Holdings, Inc.
Amarantus BioScience Holdings (AMBS) is a biotechnology company developing treatments and diagnostics for diseases in the areas of neurology, psychiatry, ophthalmology and regenerative medicine. AMBS' Therapeutics division has development rights to eltoprazine, a Phase 2b ready small molecule indicated for Parkinson's disease levodopa-induced dyskinesia, adult ADHD and Alzheimer's aggression, and owns the intellectual property rights to a therapeutic protein known as mesencephalic-astrocyte-derived neurotrophic factor (MANF) and is developing MANF-based products as treatments for brain and ophthalmic disorders. AMBS' Diagnostics division owns the rights to MSPrecise®, a proprietary next-generation DNA sequencing (NGS) assay for the identification of patients with relapsing-remitting multiple sclerosis (RRMS) at first clinical presentation, has an exclusive worldwide license to the Lymphocyte Proliferation test (LymPro Test®) for Alzheimer's disease, which was developed by Prof. Thomas Arendt, Ph.D., from the University of Leipzig, and owns intellectual property for the diagnosis of Parkinson's disease (NuroPro). AMBS also owns the discovery of neurotrophic factors (PhenoGuard) that led to MANF's discovery.
For further information please visit www.Amarantus.com, or connect with the Company on Facebook, LinkedIn, Twitter and Google+.
Forward-Looking Statements
Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are forward-looking statements. These forward-looking statements generally are identified by the words "believes," "project," "expects," "anticipates," "estimates," "intends," "strategy," "plan," "may," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain. Factors which could have a material adverse effect on our operations and future prospects on a consolidated basis include, but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements.
Investor and Media Contact:
Jenene Thomas
Jenene Thomas Communications, LLC
Investor Relations and Corporate Communications Advisor
T: (US) 908.938.1475Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on developing therapeutic and diagnostic products for neurological disorders and orphan indications, announced that it has reported preliminary data from the blood-based version of its MSPrecise® diagnostic, the Company's proprietary multiple sclerosis (MS) diagnostic test.

MSPrecise, a next-generation DNA sequencing (NGS) assay, measures DNA mutations found in rearranged immunoglobulin genes in immune cells (B cells) to identify patients with relapsing-remitting multiple sclerosis (RRMS) at first clinical presentation.

Results from the most recent MSPrecise validation study using cerebrospinal fluid (CSF) samples for MS, reported in January 2015, demonstrated an 86% sensitivity and 71% specificity in correctly identifying early-stage RRMS in subjects being evaluated for a demyelinating disease undergoing the current diagnostic standard of care (clinical evaluation, magnetic resonance imaging and oligoclonal banding tests), as adjudicated by an expert panel of physicians. When combined with oligoclonal banding tests (OCB), sensitivity improved to 96% and specificity improved to 83%.

Today, Amarantus Diagnostics, a wholly-owned subsidiary of Amarantus BioScience Holdings, Inc., reported preliminary MSPrecise blood assay results from the same study (collected concurrently with CSF from the same patients). In the study, preliminary results indicate that the MSPrecise blood assay exhibited an 81% sensitivity and 89% specificity for identifying early-stage RRMS in subjects being evaluated for a demyelinating disease undergoing the current diagnostic standard of care. These results have not yet been combined with OCB and will require replication prior to moving into a CLIA validation study.

"These early findings are encouraging, and provide a pathway to further define and refine the MSPrecise blood assay," commented Colin Bier, Chief Development Officer of Amarantus Diagnostics. "Of particular importance, in this initial blood study, is the promising and positive analytical performance. There is such a high rate of misdiagnosis of MS, especially upon first clinical presentation of this chronic and extremely debilitating disease, that a blood test would be of great benefit to patients and physicians. We are preparing MSPrecise CSF for a CLIA-enabling validation study and, in parallel, will actively continue research and development of the MSPrecise blood assay."

"MSPrecise is potentially a groundbreaking advancement for the diagnosis of multiple sclerosis. Based on the CSF validation data, we anticipate moving into a CLIA validation that is currently in the planning stages," added Gerald E. Commissiong, President & CEO of Amarantus BioScience Holdings, Inc. "The MSPrecise CSF assay, along with our LymPro Test® blood diagnostic for Alzheimer's disease, are the two of key assets in our diagnostics division. Together, MSPrecise and LymPro will allow Amarantus Diagnostics to very rapidly achieve critical mass as one of the premier neurodiagnostic testing companies in the world."

LymPro is currently available as a diagnostic assay for Investigational Use Only (IUO) in pharmaceutical therapeutic clinical development programs. Amarantus plans to advance MSPrecise and LymPro into CLIA validation studies in parallel later this year to prepare for the launch of MSPrecise and LymPro under the CLIA designation for marketing to the broader medical community in the United States.

- See more at: http://globenewswire.com/news-release/2015/05/11/734485/10133691/en/Amarantus-Reports-Preliminary-Data-From-Blood-based-Version-of-MSPrecise-R-Diagnostic-for-Multiple-Sclerosis.html#sthash.TYLVRqzE.dpuf
- See more at: http://globenewswire.com/news-release/2015/05/11/734485/10133691/en/Amarantus-Reports-Preliminary-Data-From-Blood-based-Version-of-MSPrecise-R-Diagnostic-for-Multiple-Sclerosis.html#sthash.QTB273lO.dpuf









Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on developing therapeutic and diagnostic products for neurological disorders and orphan indications, announced that it has reported preliminary data from the blood-based version of its MSPrecise® diagnostic, the Company's proprietary multiple sclerosis (MS) diagnostic test.

Read more »

 

Non-Significant Associations Between Measures of Inhibitory Control and Walking While Thinking in Persons with Multiple Sclerosis: STUDY

Monday

 

Uhtoff's phenomenon in MS





















































Image source: SUDDENLYMS.COM

One of the first signs of multiple sclerosis is Uhthoff’s phenomenon, episodes of blurry or dimmed vision associated with a rise in body temperature. Why does this happen and what can you do about it?
Sensitivity to heat affects up to 80 percent of people who have multiple sclerosis. While increases in core body temperature can result in a worsening of a variety of symptoms related to MS, blurry vision is the most common one.
Read more »

 

Researchers Solve Multiple Sclerosis Puzzle






















Image source: MIT

Evidence has long suggested multiple sclerosis (MS) is an autoimmune disease, but researchers have been puzzled because they found the same T cells that attack the myelin sheathing around nerve cells in MS patients are present in healthy subjects as well.
Read more »

 

Tips for Patients with Multiple Sclerosis: Dietary























Image source: Flickr; Allan Ajifo/”brain power”

Liskula Cohen discusses the dietary changes she’s had to make as a result of being diagnosed with Multiple Sclerosis
Read more »

 

Gene sheds light on development of type 1 diabetes, autoimmune disease.



























When the researchers turned off the Clec16a gene in diabetes-prone mice, most of the animals did not develop the disease

Type 1 diabetes and multiple sclerosis are types of autoimmune disease - where the immune system attacks the body's own tissue. Autoimmunity is a complex process, and scientists do not fully understand how it begins. Now, a new study finds an important clue in a gene called Clec16a that appears to control how immune system T cells are primed to attack targets.
Read more »

 

Specific brain chemical may play role in promoting chronic pain





































Image source: SUSAN-DEBORAH

A chemical in the brain typically associated with cognition, movement and reward-motivation behavior -- among others -- may also play a role in promoting chronic pain, according to new research at The University of Texas at Dallas.
Read more »

Labels:


 

Pallidal and caudate volumes correlate with walking function in MS: STUDY

























Image Source: GALLERYHIP
Read more »

Labels: ,


Sunday

 

Anita Cunningham talks about her brave husband Tony and how he is coping with primary progressive MS

























Anita Cunningham, from Billericay, was a childhood carer for her mum Linda, who had a rare form of multiple sclerosis.
Read more »

Labels: ,


 

Make a Splash with the Multiple Sclerosis Association of America This Memorial Day: VIDEO


























CHERRY HILL, N.J., May 14, 2015 /PRNewswire/ -- For the more than 400,000 Americans living with multiple sclerosis (MS), the support and resources available from organizations such as the Multiple Sclerosis Association of America (MSAA) are crucial to improving quality of life. Swim for MS – an ongoing national fundraiser – helps MSAA provide much-needed vital services and support for the MS community.
Read more »

Labels:


 

An entirely new way to think about MS?: VIDEO


























Hi. I'm Dr Stephen Krieger, a neurologist at the Corinne Goldsmith Dickinson Center for Multiple Sclerosis at Mount Sinai Hospital in New York. I'm here at the American Academy of Neurology meeting in Washington, DC, where I had the chance to present for the first time a new visualization of multiple sclerosis (MS) disease course that I call "The Topographical Model of MS," so I thought I would show that to you and present it here.
Read more »

Labels:


 

Study implicates new gene in MS disease activity.



























Demyelination by MS. The CD68 colored tissue shows several macrophages in the area of the lesion. Original scale 1:100. Credit: Marvin 101/Wikipedia

A new study led by investigators at Brigham and Women's Hospital (BWH) reports the discovery of a genetic variant that is associated with a patient's likelihood of responding to interferon-beta, one of the medications used in treating multiple sclerosis (MS). Published in the Annals of Neurology on May 14, the study also presents evidence that the affected gene, SLC9A9, may have a broader role in regulating the development and activity of certain immune cells that play important roles in inflammatory diseases like MS.
Read more »

Labels:


 

A Pilot Study: examining the effects and tolerability of structured dance intervention for individuals with multiple sclerosis

























Image source: SALSACHACHA.COM
Read more »

Labels:


Saturday

 

Q&A With Sibyl E. Wray, MD, From Hope Neurology Multiple Sclerosis Center: Survey Shows Patients Want More Involvement in MS Treatment: VIDEO

 

"Overcoming the Challenge of Progressive Multiple Sclerosis" Important Topic at CMSC Annual Meeting
























Dr. Alan Thompson

Dr. Alan Thompson Delivers Donald Paty Memorial Lecture at MS Conference for Healthcare Professionals
Read more »

Labels: ,


 

Allegheny General Hospital Introduces New Treatment for Relapsing Multiple Sclerosis










































Allegheny General Hospital, part of Allegheny Health Network, is the first hospital in the western Pennsylvania region to offer Lemtrada, a new treatment for multiple sclerosis which is providing hope for patients who haven't had success with other MS drugs.
Read more »

Labels:


 

Time to Rethink CIS Criteria















Jagannadha R. Avasarala, M.D.

About 20% of patients do not meet the diagnostic criteria of clinically isolated syndrome (CIS) based on radiological and clinical evidence. Patients who do not fit the CIS diagnostic criteria may yet have oligoclonal bands distinct to CSF, increased IgG synthesis rate and IgG index and must be treated as if they carried a diagnosis of CIS.
Read more »

 

Doctors and patients don't agree: cross sectional study of patients' and doctors' perceptions and assessments of disability in multiple sclerosis: STUDY

Image source: RENEGADEHEALTH

Read more »

Labels:


Friday

 

Tender loving research helping people with MS: VIDEO



























Dr. Mark Freeman

The latest edition of our Tender Loving Research video blog features Dr. Mark Freedman remembering the patient who first inspired him to specialize in multiple sclerosis research.
Read more »

Labels:


 

La Junta resident honored with Hope Award




Jill Manley receives the Hope Award from Dr. Diana Bowling at recent Cindy Acree Hope Award function

Living with multiple sclerosis requires courage – every moment of every day. Just getting out of bed can be a process of endurance, but for La Junta resident Jill Manley, there is no question there are things to do each day that are motivating.
Read more »

Labels:


 

Researchers investigate massage to help Multiple Sclerosis patients



























Image source: MALTINGSTRAINING


People with M.S. can have fatigue, muscle pain or weakness and difficulty with motion.
Read more »

Labels:


 

Oral Drugs May Reduce Preference for Injectable Drugs in Multiple Sclerosis Treatment

Frost & Sullivan recently published a report entitled “A Product and Pipeline Analysis of the Multiple Sclerosis Therapeutics Market” providing insight into the global multiple sclerosis (MS) drug market. In this report, a competitive evaluation of MS pharmaceutical drugs currently available in the market and experimental drugs in Phase 3 trials was performed.
Read more »


Go to Older News